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Abstract 
Purpose: To formulate piroxicam-loaded lipospheres and evaluate their in vitro and in vivo properties. 
Method: Piroxicam-loaded lipospheres were prepared by hot homogenization technique using dika wax 
and Phospholipon
®
 90G (1:1, 1:2 and 2:1) as the lipid matrix. Characterisation, based on particle size 
and morphology, pH, drug content and encapsulation efficiency, were carried out on the lipospheres. In 
vitro release was evaluated in simulated intestinal fluid (pH 7.5). Anti-inflammatory and ulcerogenic 
properties of the piroxicam-loaded lipospheres were studied using healthy, adult Wistar rats. 
Result: Photomicrographs revealed spherical particles in the range of 1.66 – 3.56 µm. The results also 
indicated that lipospheres formulated with lipid matrix 1:1 and containing 0.25 % piroxicam had the 
highest encapsulation efficiency of 84 %. In vitro release data showed that lipospheres formulated with 
lipid matrix having higher concentration of dika wax exhibited the fastest drug release of drug with 
maximum release time between 60 - 70 min.  The lipospheres exhibited good anti-inflammatory 
properties with 58.6 % oedema inhibition at 5 h. Piroxicam-loaded liposheres had an ulcer index of zero 
while, the reference (plain piroxicam) had an ulcer index of 15.00 ± 1.23 (p < 0.05). 
Conclusion: Piroxicam lipospheres formulated with a mixture of dika wax and phospholipid exhibited 
good in vitro and in vivo properties. 
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INTRODUCTION
The rapid growth in the use of lipid-based drug 
delivery systems is primarily due to the diversity 
and versatility of pharmaceutical grade lipid 
excipients and their compatibility with liquid, 
semi-solid and solid drugs [1]. The increasing 
availability of lipidic excipients with specific 
characteristics offer flexibility of application with 
respect to improving the bioavailability of poorly 
water soluble drugs and manipulating their 
release profile [2].  
Dika wax is an edible vegetable fat derived from 
the kernel of Irvingia gabonensis Var excelcia 
[3,4]. It is a completely biodegradable 
physiological lipid, and like other lipid excipients, 
it has a GRAS (generally regarded as safe) 
status. Therefore, the danger of use of synthetic 
polymer matrix forming materials which may be 
associated with detrimental effects on 
incorporated drug during manufacturing of 
formulations or during the erosion of the 
polymers after application is completely avoided 
[5]. 
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Lipospheres are restricted to the stabilizing 
material of a phospholipid layer [6]. The 
combination of a solid inner core and a 
phospholipid exterior confers several advantages 
on the lipospheres compared with conventional 
microspheres, such as high dispersibility in an 
aqueous medium, and a release rate for the 
entrapped substance that is controlled by 
phospholipid coating and carrier [6,7].  
Piroxicam is a non-steroidal anti-inflammatory 
drug (NSAID) with pronounced anti-
inflammatory, analgesic and anti-pyretic effect. 
The study was aimed at evaluating piroxicam-
loaded lipospheres formulated with dika wax and 
phospholipid (Phospholipon
®
 90G) both in vitro
and in vivo in order to improve the oral 
bioavailability of piroxicam and reduce its 
ulcerative properties.  
EXPERIMENTAL 
Materials  
The following materials were used as procured 
from their suppliers without further purification: 
piroxicam (Pfizer, Nigeria), n–hexane, ethyl 
acetate (Sigma–Aldrich, Germany), hydrochloric 
acid, sodium hydroxide, monobasic potassium 




Phospholipid GmbH, Köln, Germany), activated 
charcoal (Bio–Lab, London), and sorbitol (Across 
Organics, Germany). Dika fat was extracted from 
Irvingia gabonensis seed in our laboratory. All 
other reagents and solvents were of analytical 
grade. 
Extraction and purification of dika wax from 
Irvingia gabonensis  
Irvingia gabonensis seed were purchased from 
Nsukka market, Enugu State, Nigeria in the 
month of July, 2011. It was authenticated by Mr 
AO Ozioko, a consultant taxonomist with the 
International Center for Ethnomedicine and Drug 
Development (InterCEDD), Nsukka, Nigeria, and 
a voucher specimen (no 151) was deposited in 
the herbarium of the Department of 
Pharmacognosy and Environmental Medicines, 
University of Nigeria, Nsukka. 
Dried seeds of Irvingia gabonensis was milled 
using a hammer mill. The fat was extracted in a 
Soxhlet apparatus using n–hexane [8]. The 
solvent was allowed to evaporate at room 
temperature and boiled distilled water, which was 
about twice the volume of the latter, was poured 
into the molten fat in order to dissolve the 
hydrophilic gum in the fat. The dissolved gum 
was removed with the aid of a separating funnel. 
Next, ethyl acetate was similarly used to remove 
the hydrophobic gum in the fat. The extracted fat 
was further purified by passing it through a 
column of activated charcoal and bentonite (2:1) 
at 100 
o
C at a ratio of 10 g fat to 1 g column 
material. The fat was stored in a refrigerator until 
used [2].
Preparation of lipid matrix  
Mixtures (1:1, 1:2 and 2:1 w/w) of Phospholipon
®
90G, a purified lecithin, and dika wax were 
melted in a beaker and stirred at a temperature 
of 70 
o
C using a magnetic stirrer, until a 
homogenous, transparent yellow liquid was 
obtained. The homogenous mixture was stirred 
at room temperature until congealed to ensure 
adequate mixing [9].
Preparation of lipospheres 
Piroxicam-loaded lipospheres were prepared 
using lipid matrix by hot homogenization 
technique using Ultra-Turrax
® 
(T25 Basic Digital, 
Germany). Briefly, 5 g of the lipid matrix was 
melted at 70 
o
C in a crucible and the appropriate 
amount of piroxicam (0.25, 0.5 or 0.75 g) was 
incorporated into the lipid melt. Sorbitol (4 g) was 
dissolved in hot distilled water at the same 
temperature, mixed with Tween 80 (2.5 ml) and 
poured at 70 
o
C into the molten lipid phase under 
high shear homogenization of 5000 rpm for 5 
min. An o/w emulsion was formed by phase 
inversion and allowed to cool at room 
temperature to generate the solid lipid 
microparticles (SLMs) [10]. The lipospheres (in 
emulsion form) were then stored in an amber 
coloured bottle until used. 
Determination of liposphere particle size and 
morphology  
A small quantity of the lipospheres were placed 
on a microscope slide, the slide was covered 
with a cover slip and imaged under a Hund
®
binocular microscope (Weltzlar, Germany), fitted 
with a motic image analyzer (Moticam, China) at 
a magnification of x 400. Different portions of the 
SLMs from each batch were sampled and 
counted (n = 100) with the image analyzer, and 
the mean value computed. 
Determination of drug content  
Beer’s plot was obtained at the concentration 
range of 0.2 - 1.0 mg % for piroxicam in 
simulated intestinal fluid (SIF, pH 7.5). For each 
batch, 10 ml of SLMs was centrifuged (Chem. 
Lab. Instrument, UK) for 30 min at 1500 rpm. 
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The sediment was used in the analysis of drug 
content. A sample of 0.5 g of SLMs was 
triturated in a mortar and pestle with 10 ml of SIF 
(pH 7.5), transferred to a 100 ml volumetric flask 
and made up to volume with SIF. The solution 
was filtered through a filter paper (Whatman no. 
1) and analyzed spectrophotometrically at a 
wavelength of 370 nm (Jenway 6305, UK). Drug 
concentrations were calculated with reference to 
the Beer’s plot. 
Drug encapsulation efficiency  
Encapsulation  efficiency (EE) was calculated 
as in Eq 1. 
where ADC is the actual drug content and TDC 
is the theoretical drug content.  
pH analysis
The pH of the SLMs were determined over a 
period of time (24 h, 1 week, 2 months and 3 
months) using a pH meter (Suntex TS – 2, 
Taiwan).
Evaluation of drug release studies  
The USP paddle method was adopted in this 
study. The dissolution medium consisted of 900 
ml of freshly prepared simulated intestinal fluid 
(SIF, pH 7.5) maintained at 37 ± 1 
o
C. The 
polycarbonate dialysis membrane (MW 5000, 
Spectrum Labs, Brenda, Netherlands) selected 
was pretreated by soaking it in the dissolution 
medium for 24 h prior to use. A quantity of SLM 
equivalent to 0.020 g piroxicam was taken from 
each batch, placed in a polycarbonate dialysis 
membrane containing 2 ml of the dissolution 
medium, securely tied with a thermo–resistant 
thread and placed in the chamber of the release 
apparatus. The paddle was rotated at 100 rpm, 
and at predetermined time intervals, 5 ml 
aliquots of the dissolution medium was 
withdrawn, appropriately diluted, and analyzed 
for drug content spectrophotometrically. Sink 
conditions were maintained by replenishing the 
medium with 5 ml of fresh dissolution fluid after 
each withdrawal. The amount of drug released at 
each time interval was determined with reference 
to Beer’s Plot. 
Anti-inflammatory studies  
The anti–inflammatory activity of the piroxicam-
loaded lipospheres was evaluated using the rat 
paw oedema test [11]. All animal experimental 
protocols were carried out in accordance with the 
guidelines of the Animal Ethics Committee of the 
Faculty of Pharmaceutical Sciences, University 
of Nigeria, Nsukka and in compliance with the 
Federation of European Laboratory Animal 
Science Association and the European 
Community Council Directive of November, 1986 
(86/609/EEC). The phlogistic agent employed in 
the study was fresh undiluted egg albumin. Adult 
Wistar rats of either sex (150 – 200 g) were 
divided into five groups. The animals were fasted 
and deprived of water for 12 h prior to the 
experiment. Lipospheres equivalent to piroxicam 
10 mg/kg body weight was administered orally to 
the rats. The reference group received 10 mg/kg 
of pure sample of piroxicam, while the control 
group received normal saline 5 ml/kg. Thirty 
minutes post-treatment, oedema was induced by 
injection of 0.1 ml fresh undiluted egg albumin 
into the sub plantar region of the right hind paw 
of the rats. The volume of distilled water 
displaced by treated right hind paw of the rats 
were measured using plethysmometer before 
egg albumin administration and at 30 min, 1, 2, 
3, 4, 5 and 6 h after egg albumin injection. 
Inhibition of oedema was calculated using Eq 2. 
 Inhibition (%) = …………. (2) 
where Vt is the volume of oedema at any 
particular time and Vo is the volume of oedema 
in control rats at the same time [12,13].   
Ulcerogenicity of lipospheres
The ulcerogenicity of piroxicam–loaded 
lipospheres was determined using a method 
described by Chung-Chin et al [14].  The studies 
were carried out on healthy Wistar rats (180 – 
220 g). The animals were divided into four 
groups (n = 5). The control group received 
normal saline, the test group received SLMs 
equivalent to 10 mg/kg piroxicam (A1 and B1), 
while the reference group received 10 mg/kg 
pure sample of piroxicam orally. Prior to the test,
the animals were fasted for 8 h but allowed free 
access to food and water, and sacrificed 8 h after 
administration of treatment. The gastric mucosa 
of each rat was examined under a microscope 
fitted with a 4 x binocular magnifier, and the 
number of lesions counted. The mean score of 
each treated group minus the mean score of the 
control group was taken as severity index of 
gastric damage.   
Statistical analysis 
Statistical analysis of the data was carried out 
using SPSS, version 14.0 (SPSS Inc. Chicago, 
IL.USA). All values are expressed as mean ± 
standard deviation (SD). Data were analysed by 
one-way ANOVA. Differences between means 
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were assessed by a two-tailed Student’s t-test. 
Differences were considered statistically 
significant at p < 0.05. 
RESULTS   
Particle characteristics 
The photomicrographs presented in Fig 1 shows 
that piroxicam-loaded lipospheres formulated 
were spherical in shape. Plain SLMs, i.e., without 
piroxicam, had particle sizes ranging from 0.47 ± 
0.04 to 0.51 ± 0.07 µm which were significantly 
(p < 0.05)  lower than those of SLMs containing 
piroxicam (1.66 ± 3.18 to 3.56 ± 2.95), as 
presented in Table 1. 
pH of lipospheres 
Table 1 shows pH values of the lipospheres over 
a period of 1 month. pH varied from between 
6.11 ± 0.19 and 6.57 ± 0.11 within 24 h of 
preparation to between 5.58 ± 0.10 and 6.38 ± 
0.15 over the next 1 month.  
Encapsulation efficiency (EE)
As indicated in Table 1, EE of the lipospheres 
ranged from 24 % for batch C3 to 84 % for batch 
A1. Piroxicam-loaded lipospheres containing 
0.25 % of piroxicam had the highest 
encapsulation efficiency of 76 % for batch B1 
lipospheres and 84 % for batch A1 lipospheres. 
Drug release from piroxicam-loaded 
lipospheres 
The drug release profile presented in Fig. 2 show 
that all the piroxicam-loaded lipospheres 
exhibited good drug release. The lipospheres 
formulated with higher content of phospholipid 
(2:1) in the lipid matrix, i.e., batches C1 to C3 
greater prolonged drug release behaviour with 
maximum drug release at 120 min. However, 
piroxicam-loaded lipospheres formulated with LM 
containing phospholipid: dika wax in 1:1 showed 
maximum drug release ranging from 70 min for 
batches A1 and A3 to 80 min for batch A2. 
        
A1                     B1      C1 
Fig. 1: Photomicrographs of representative samples of piroxicam-loaded lipospheres formulated with 1:1, 1:2 and 
2:1 %w/w (A1, B1 and C1) of lipid matrix (Phospholipid: dika wax) and containing 0.25 % piroxicam respectively, 
magnification x 400. 
 Table 1: Some physicochemical properties of piroxicam-loaded lipospheres  
pH Batch LM 











A0 1:1 6.34 ± 0.21 6.10 ± 0.27 6.00 ± 0.13 0.47 ± 0.04  0.00  0.00 - 
A1 1:1 6.37 ± 0.17 6.00 ± 0.12 5.58 ± 0.10 3.13 ± 3.00  0.21 ± 0.27 0.25 84.0 
A2 1:1 6.46 ± 0.14 6.32 ± 0.17 6.15 ± 0.11 2.09 ± 3.13 0.12 ± 0.32 0.50 24.0 
A3 1:1 6.48 ± 0.27 6.42 ± 0.15 6.38 ± 0.15 3.08 ± 2.88 0.13 ± 0.47 0.75 17.3 
B0 1:2 6.11 ± 0.19 6.07 ± 0.11 6.00 ± 0.25 0.50 ± 0.03  0.00 0.00 - 
B1 1:2 6.15 ± 0.20 6.04 ± 0.23 2.89 ± 3.03  0.19 ± 0. 21 0.25 76.0 
B2 1:2 
6.37 ± 0.11 
6.43 ± 0.10 6.38 ± 0.17 6.09 ± 0.15 2.89 ± 3.03  0.15 ± 0.39 0.50  30.0 
B3 1:2 6.57 ± 0.11 6.24 ± 0.21 6.00 ± 0.11 3.56 ± 2.95 0.24 ± 0.27 0.75 31.0 
C0 2:1 6.12 ± 0.17 6.08 ± 0.20 6.00 ± 0.17 0.51 ± 0.07  0.00 0.00 - 
C1 2:1 6.38 ± 0.12 6.20 ± 0.16 6.10 ± 0.12 3.10 ± 1.02  0.08± 0.23 0.25 31.5 
C2 2:1 6.41 ± 0.07 6.37 ± 0.17 6.10 ± 0.13 3.24 ± 2.91  0.14 ± 0.19 0.50 27.0 
C3 2:1 6.51 ± 0.09 6.18 ± 0.12 5.89 ± 0.27 1.66 ± 3.18  0.18 ± 0.24 0.75 24.0 
a
n = 100, SD = Standard deviation; 
b
n = 5; A0 – A3 contain LM 1:1; B0 - B3 contain LM 1:2; C0 – C3 contain LM 2:1; A0, B0 and 
C0: contain no drug; LM = lipid matrix 
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  (a)                        (b)           (c) 
Fig. 2:  Release profile of piroxicam loaded lipospheres: (a) A1,  B1 and  C1 contain LM 1:1, 1:2 and 2:1, 
respectively, as well as 0.25 % piroxicam; (b)  A2,  B2,  C2 contain 0.5 % piroxicam; (c)  A3,  B3 and  C3 
contain 0.75 % piroxicam. 
Table 2: Anti-inflammatory properties of piroxicam-loaded lipospheres 
Paw oedema volume (ml ± SD)
a
  Group 
0.5 h 1 h 2 h 3 h 4 h 5 h 
A1 0.58 ± 0.23* 
(27.5) 
0.55 ± 0.27* 
(35.3) 
0.48 ± 0.19*  
(40.7) 
0.42 ± 0.29* 
(46.8) 
0.35 ± 0.12* 
(53.3)
0.30 ± 0.17* 
(57.1) 
B1 0.56 ± 0.37* 
(30.0) 
0.58 ± 0.45* 
(31.8) 
0.50 ± 0.13* 
(38.3) 
0.40 ± 0.32* 
(49.4) 
0.35 ± 0.24* 
(53.3) 
0.29 ± 0.21* 
(58.6) 
C1 0.60 ± 0.52* 
(25.0) 
0.55 ± 0.47* 
(35.3) 
0.51 ± 0.54* 
(37.0) 
0.43 ± 0.39* 
(43.0) 
0.37 ± 0.45* 
(50.7) 
0.30 ± 1.52* 
(57.1) 
D (ref.) 0.60 ± 0.24* 
(25.0) 
0.57 ± 0.43* 
(33.0) 
0.50 ± 0.57* 
(38.3) 
0.45 ± 0.51* 
(43.0) 
0.40 ± 0.23*  
(46.7) 
0.31 ± 0.27* 
(55.7) 
E(Cont.) 0.80 ± 0.35 0.85 ± 0.17 0.81 ± 0.27 0.79 ± 0.13 0.75 ± 0.21 0.70 ± 0.12 
* significant difference at p < 0.05 compared to control. values are mean ± SD (n = 5); 
a 
values in parenthesis are % oedema 
inhibition; A1 – C2 = piroxicam-loaded lipospheres, D = pure piroxicam (reference); E = negative control ( normal saline).
Anti-inflammatory properties 
The anti-inflammatory results, presented in Table 
2, show that piroxicam-loaded lipospheres 
exhibited good anti-inflammatory activity that was 
significantly higher than that of the control group 
(p < 0.05). The oedema inhibition ranged from 
35.3 to 53.3 % for piroxicam-loaded lipospheres 
(A1) while the reference drug showed inhibition 
of 25 to 47 %.  
Ulcerogenic properties 
The results of ulcerogenic studies are presented 
in Table 3. Piroxicam lipospheres did not show 
ulcer-inducing potentials. However, the reference 
drug (plain piroxicam) showed a high ulcer index 
of 15.00 ± 1.23 which was significantly higher 
than that of the piroxicam-loaded liposheres and 
negative control (p < 0.05).  
DISCUSSION 
Increase in the amount of piroxicam 
encapsulated increased also the particle size of 
the lipospheres. This is in agreement with the 
findings of Barakat et al [15] who evaluated 
carbamazepine–loaded precifac lipospheres. 
Joseph et al [16], who studied piroxicam-loaded 
polycarbonate microspheres made a similar 
observation. The formulations also exhibited 
stable pH from 24 h to 1 month. Therefore, there 
was no degradation of the API and excipients.  
Table 3: Ulcerogenic properties of piroxicam 
lipospheres 
Batch Ulcer index 
(mean ± SD)
a
A1 0.00 ± 0.00
B1 0.00 ± 0.00
D (reference) 15.00 ± 1.23*
E (control) 0.00 ± 0.00
*Significant at p < 0.05 compared to control. 
a
n = 5; A1 and 
B1: piroxicam-loaded  SLMs; D: piroxicam pure sample; E: 
normal saline. 
Generally, encapsulation efficiency (EE) was 
affected by the lipid composition/ratio used in 
formulating the lipospheres. The reason may be 
the presence of small amounts of fat in the inner 
core of the lipospheres which can lead to 
saturation of the fat core of the lipospheres by 
the drug incorporated in the dispersion. EE of 
piroxicam-loaded lipospheres was also inversely 
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affected by the total amount of drug in the 
dispersion.  
The SLMs had reproducible drug release in all 
the batches, without any evidence of ‘burst 
effect’. However, the rate of drug release was 
affected by the ratio/combination of the lipid used 
in preparation of the lipid matrix. Lipid matrices 
having higher amount of dika wax showed faster 
release of drug than lipospheres with higher 
phospholipid concentration. This may be due to 
diffusion of the drug from the inner core of the 
lipospheres through the phospholipid coating to 
the surface of the lipospheres. 
The piroxicam-loaded lipospheres showed higher 
inhibition of oedema than the reference (plain 
piroxicam). This may be due to increased 
absorption of drug in vivo in the presence of the 
lipid matrix carrier. Drugs suspended in lipid 
matrix have been shown, in most cases, to be 
better absorbed than those incorporated in 
conventional solid dosage forms [1]. This could 
be due to the ease of wetting of hydrophobic 
drug particles in the presence of lipid matrix [2]. 
The presence of surfactant in the formulation 
may further promote drug release [2].  
Piroxicam-loaded lipospheres drastically reduced 
the ulcerogenic potentials of piroxicam. This may 
be due to the presence of the phospholipid in the 
formulations which might have helped to shield 
or protect the gastric mucosa from irritation by 
the drug which is a non-steroidal anti-
inflammatory drug (NSAID). Our finding is in 
agreement with that of Lichtenberger et al [17], 
who proposed that pre-associating NSAIDs with 
zwitterionic phospholipids prior to their 
administration should reduce the ability of the 
NSAIDs to associate the phospholipids in the 
mucus gel, and should thus reduce their 
ulcerogenicity.  
CONCLUSION
Dika wax and Phospholipon
®
 90G presented 
good matrix for the formulation of piroxicam-
loaded lipospheres. In vitro and in vivo studies 
undertaken with the lipospheres provided 
positive results, thus indicating the need for 
further development and optimization of the 
formulation. The lipospheres exhibited good anti-
inflammatory properties as well as minimal 
ulcerogenic potentials. Piroxicam-loaded 
lipospheres based on dika wax matrices have 
advantages over the commercial formulations of 
piroxicam, include low excipient and processing 
costs. 
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